SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy

SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.

Bibliografische gegevens
Hoofdauteur:	Meem, Manila
Andere auteurs:	Akter, Dr. Raushanara
Formaat:	Thesis
Taal:	English
Gepubliceerd in:	Brac University 2023
Onderwerpen:	Cancer SHP2 inhibitors Targeted therapy Catalytic inhibitor Allosteric inhibitor. Cancer research.
Online toegang:	http://hdl.handle.net/10361/18081

Gelijkaardige items

A review on potential of PARP inhibitors in the treatment of prostate cancer
door: Islam, Saidul
Gepubliceerd in: (2022)

RIPK pathway, as a potential target, for cancer treatment - a review
door: Jahan, Nusrat
Gepubliceerd in: (2024)

Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
door: Flora, Sanzida Alam
Gepubliceerd in: (2024)

Immunotherapy in the Management of Lung Cancer
door: Tasnim, Humayra
Gepubliceerd in: (2022)

A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
door: Ratu, Tabassum
Gepubliceerd in: (2024)

Recent advances in Cancer treatment targeting autophagy and future aspects
door: Emon, Kamrul Hasan
Gepubliceerd in: (2022)

Identification of FAP inhibitors using in silico simulation study
door: Deeba, Maliha Tasnim
Gepubliceerd in: (2018)

A review on the role of Epigenetics in Psychiatry: Etiology, contemporary medicine and future perspectives
door: Oshin, Sadia Afrin
Gepubliceerd in: (2021)

A review on newly approved PARP inhibitors: Talazoparib and Olaparib
door: Karim, Azrin
Gepubliceerd in: (2024)

Tamoxifen: The ideal post operative hormonal therapy to demote Ductal Carcinoma in Situ
door: Mirza, Maisa Tasnim
Gepubliceerd in: (2023)

A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
door: Khan, Muidul Hasan
Gepubliceerd in: (2024)

A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease
door: Haque, Mushfiqul
Gepubliceerd in: (2019)

A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
door: Islam, Nahidul
Gepubliceerd in: (2023)

A review on targeted therapies for lung cancer
door: Ashraf, Anushey
Gepubliceerd in: (2023)

TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
door: Afroza, Halima
Gepubliceerd in: (2024)

Comprehensive review on importance, challenges and future prospects of nanotechnology and combination therapy for Alzheimer’s disease
door: Ishrat, Nowshin
Gepubliceerd in: (2024)

A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
door: Sorno, Rubina Haque
Gepubliceerd in: (2024)

Effect Of sodium glucose co-transporter 2 inhibitors on weight reduction in overweight and obese population: A review
door: Mahin, Md. Tamjidur Rahman
Gepubliceerd in: (2024)

Targeted therapeutic options in the treatment of Breast Cancer
door: Alam, Kazi Tasnuva
Gepubliceerd in: (2022)

Immunotherapeutic approaches to treat cancer: Prospects and challenges
door: Fred, Namanda Rogers
Gepubliceerd in: (2021)

Relationship between SGLT2 inhibitor use and risk of lower limb amputations: a pharmacovigilance study
door: Khandker, Tahia Anjum
Gepubliceerd in: (2024)

Synthesis and sar o acne medication
door: Naureen, Tasnia
Gepubliceerd in: (2024)

HPLC method development for the analysis of linagliptin
door: Mimiya, Ruhani Amrin
Gepubliceerd in: (2020)

Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
door: Paul, Pulock
Gepubliceerd in: (2024)

Therapeutic prospective of targeting calcium homeostasis in cancer – a review
door: Kamal, Tasnova
Gepubliceerd in: (2019)

Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
door: Tania, Umme
Gepubliceerd in: (2023)

Trend in approval of targeted biologics in the last two decades
door: Siddika, Khadiza
Gepubliceerd in: (2024)

Breast cancer therapy through Liposomal drug delivery system
door: Ome, Nusrat Jahan
Gepubliceerd in: (2024)

Epigenetic therapy in cancer
door: Abid, Md. Shadman Ridwan
Gepubliceerd in: (2021)

A review on triple-negative breast cancer and its potential treatment
door: Niasa, Jannatul Ferdous
Gepubliceerd in: (2023)

Recent developments in the Adeno-Associated Viral Gene Therapy for Non-Small Cell Lung Cancer during the past 20 years
door: Razna, Amrin Islam
Gepubliceerd in: (2019)

Drug repurposing: potential of Antimicrobial Drugs in Breast Cancer Treatment
door: Chakraborty, Anuradha
Gepubliceerd in: (2024)

A review on nanoparticles based drug delivery in cancer treatment: advantages & challenges
door: Nahar, Kamrun
Gepubliceerd in: (2023)

The impact of cell penetrating peptides in prospective cancer therapy: a review
door: Nashrah, Zannatul
Gepubliceerd in: (2023)

A review on the recent advancements on nanoparticles drug delivery approaches in anti-cancer treatment
door: Hoque, Syeda Mehren
Gepubliceerd in: (2024)

A review on carbon nanotube: a new era in cancer diagnosis & therapy
door: Parvez, Safi
Gepubliceerd in: (2023)

Statistics and informatics in molecular cancer research

A comprehensive review on drug repurposing in cancer treatment
door: Sarkar, Onusree
Gepubliceerd in: (2024)

An examination of therapeutic synergy: a comprehensive meta-analysis comparing the efficacy of TAS-102 and FOLFOX as a combination therapy for colon cancer
door: Hasan, Amit
Gepubliceerd in: (2024)

Art therapy to improve quality of life of cancer patients and their carers in Bangladesh
door: Dowla, Rumana, et al.
Gepubliceerd in: (2022)